Pfizer: Ignoring The Dead Cat Bounce

Dair Sansyzbayev9.81K FollowersFollow5ShareSavePlay(9min)CommentsSummaryPfizer is reiterated as a 'Hold' due to structural challenges, despite a recent 12% total return and a compelling 6.7% dividend yield.PFE faces a significant patent cliff by 2028, high leverage, and lagging profitability versus peers, limiting its financial flexibility for growth.Recent double-beat earnings mask underlying YoY declines in revenue, EPS, and free cash flow, highlighting ongoing operational headwinds.While PFE trades at historically low multiples and offers income appeal, sustainable shareholder value growth remains doubtful given current fundamentals. Alexandros Michailidis/iStock Editorial via Getty Images Pfizer Inc. (PFE) has been outperforming over the last three months with a 12% total return since my previous "Hold" rating. In my opinion, it was more like a "dead cat bounce" rather thanThis article was written byDair Sansyzbayev9.81K FollowersFollowI am a highly experienced Chief Financial Officer (CFO) with a strong background in the oilfield and real estate industries. With over a decade of experience in finance, I have led numerous complex due diligence efforts and M&A transactions, both domestically and internationally.In recent years, I have developed a keen interest in equity research and analysis of public companies. This interest has led me to render equity research services for a Dubai-based family office with over $20 million in assets under management (AUM). My expertise in finance allows me to provide valuable insights and recommendations to clients seeking to make informed investment decisions.I pride myself on my ability to analyze financial statements, evaluate market trends, and identify key drivers of growth in different industries. I am passionate about staying up-to-date on the latest developments and trends in the equity research industry, and I am always seeking to enhance my skills and knowledge through continuing education and professional development.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.